
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Zenas BioPharma, Inc. Common Stock (ZBIO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZBIO (1-star) is a SELL. SELL since 4 days. Profits (20.65%). Updated daily EoD!
1 Year Target Price $32.14
1 Year Target Price $32.14
5 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.37% | Avg. Invested days 25 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 460.59M USD | Price to earnings Ratio - | 1Y Target Price 32.14 |
Price to earnings Ratio - | 1Y Target Price 32.14 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 5.83 - 26.25 | Updated Date 05/20/2025 |
52 Weeks Range 5.83 - 26.25 | Updated Date 05/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.89 |
Earnings Date
Report Date 2025-08-12 | When Before Market | Estimate -1.06 | Actual -1.25 |
Profitability
Profit Margin - | Operating Margin (TTM) -373.3% |
Management Effectiveness
Return on Assets (TTM) -56.7% | Return on Equity (TTM) -115.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 110831343 | Price to Sales(TTM) 30.71 |
Enterprise Value 110831343 | Price to Sales(TTM) 30.71 | ||
Enterprise Value to Revenue 22.17 | Enterprise Value to EBITDA - | Shares Outstanding 41834200 | Shares Floating 20950558 |
Shares Outstanding 41834200 | Shares Floating 20950558 | ||
Percent Insiders 21.2 | Percent Institutions 74.81 |
Upturn AI SWOT
Zenas BioPharma, Inc. Common Stock
Company Overview
History and Background
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of therapies for patients suffering from autoimmune diseases. They focus on innovative immunotherapies.
Core Business Areas
- Immunotherapy Development: Focuses on discovering and developing novel immunotherapies for autoimmune diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Commercializes approved therapies globally.
Leadership and Structure
The leadership team comprises experienced executives with expertise in drug development, commercialization, and corporate strategy. The organizational structure is typical of a biopharmaceutical company, with departments focusing on research, development, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Obexelimab: Obexelimab is a potential treatment being developed for autoimmune diseases. Specific market share data, user numbers, and revenue figures are not currently publicly available. Competitors include companies developing similar therapies, such as those targeting B cells or other immune pathways. These might include therapies targeting CD20 (rituximab).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investment in research and development. The autoimmune disease market is a large and growing segment, driven by an aging population and increased awareness of autoimmune disorders.
Positioning
Zenas BioPharma is positioning itself as a leader in the development of novel immunotherapies for autoimmune diseases. Their focus on specific targets and mechanisms of action differentiates them from some competitors.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapies is estimated to be in the tens of billions of dollars. Zenas BioPharma aims to capture a significant portion of this market with its innovative pipeline.
Upturn SWOT Analysis
Strengths
- Innovative immunotherapy pipeline
- Experienced leadership team
- Focus on unmet medical needs
- Strong research and development capabilities
Weaknesses
- Reliance on clinical trial success
- High research and development costs
- Dependence on regulatory approvals
- Limited commercialized products
Opportunities
- Expansion into new autoimmune indications
- Partnerships with larger pharmaceutical companies
- Acquisition of complementary technologies
- Accelerated regulatory pathways
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- LLY
- BMY
- ABBV
- JNJ
Competitive Landscape
Zenas BioPharma competes with large, established pharmaceutical companies and other smaller biotech firms developing autoimmune therapies. Their success depends on the differentiation and efficacy of their drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be reflected in the expansion of the pipeline and progress in clinical trials.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives could include new clinical trial starts, partnerships, and fundraising activities.
Summary
Zenas BioPharma is a clinical-stage biopharmaceutical company focusing on autoimmune disease therapies and has an innovative pipeline, though it faces risks with clinical trials. Being a small cap, Zenas BioPharma depends on future clinical trial success to deliver on their goals. They must efficiently manage resources and successfully navigate regulatory hurdles. Competition from larger companies presents a significant challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share is estimated and may not be precise. Data is current as of October 26, 2023.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zenas BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2024-09-13 | CEO & Chairman of the Board Mr. Leon Oliver Moulder Jr., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://zenasbio.com |
Full time employees 130 | Website https://zenasbio.com |
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.